首頁 > 市場調查報告書 > 製藥

疼痛

市場調查報告書

商品編碼

1361560

醫用大麻市場 - 2018-2028F 全球產業規模、佔有率、趨勢、機會和預測，按產品類型、活性成分、配銷通路、按應用、最終用戶行業、地區和競爭細分

Medical Cannabis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F Segmented By Product Type, By Active Ingredient, By Distribution Channel, By Application, By End User Industry, By Region and Competition

出版日期: 2023年10月03日 | 出版商:

TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

全球醫用大麻市場預計年複合成長率為 14.62%，到 2028 年將達到 475.8 億美元。這歸因於政府資金的增加、研發活動 (R&D) 的增加以及世界各地接受度的提高。醫用大麻市場是一個快速成長的行業，正在世界許多國家獲得接受和法律認可。

醫用大麻是指使用大麻植物或其萃取物來治療一系列疾病，包括慢性疼痛、噁心、癲癇發作和焦慮等。醫用大麻市場包括多種產品，包括乾燥大麻花、油、膠囊、酊劑和食品。這些產品可以根據患者的需求和偏好以不同的方式給藥，例如吸煙、蒸發或攝入。推動醫用大麻市場成長的主要因素之一是大眾越來越接受大麻作為合法的醫療選擇。隨著對大麻的醫療特性進行越來越多的研究，並且越來越多的患者報告使用大麻來控制病情的正面效果，對醫用大麻產品的需求正在成長。在澳大利亞，醫用大麻於2016年合法化，根據治療產品管理局的調查，醫用大麻處方數量從2017年的1,000張增加到2021年的10萬張以上。

醫用大麻市場，依產品類型：

花蕾/大麻花

大麻萃取物

醫用大麻市場（依活性成分）：

四氫大麻酚 (THC)

大麻二酚（CBD）

其他

醫用大麻市場，按配銷通路：

企業對企業

企業對消費者

醫用大麻市場，按應用：

慢性疼痛

精神錯亂

癌症

癲癇

其他

醫用大麻市場，按最終用戶分類：

製藥與生物技術公司

學術研究機構

其他

醫用大麻市場，按地區：

北美洲

美國
墨西哥
加拿大

歐洲

德國
馬爾他
英國
法國
丹麥
義大利
西班牙

亞太

澳洲
中國
泰國
韓國
印度

南美洲

巴西
阿根廷
哥倫比亞

中東和非洲

黎巴嫩
南非
以色列

競爭格局

公司簡介：全球醫用大麻市場主要公司的詳細分析。

可用的客製化：

根據給定的市場資料，TechSci Research 可根據公司的具體需求提供客製化服務。該報告可以使用以下自訂選項：

公司資訊

其他市場參與者（最多五個）的詳細分析和概況分析。

市場規模及預測
- 按價值
市佔率及預測
- 依產品類型（花蕾/大麻花、大麻萃取物）
- 依活性成分（四氫大麻酚（THC）、大麻二酚（CBD）、其他）
- 按配銷通路（B2B、B2C）
- 按應用（慢性疼痛、精神障礙、癌症、癲癇等）
- 按最終用戶產業（製藥和生物技術公司、學術和研究機構、其他）
- 按地區
- 按公司分類 (2022)
產品圖
- 依產品類型
- 按活性成分
- 按配銷通路
- 按應用
- 按最終用戶
- 按地區

第 7 章：北美醫用大麻市場展望

市場規模及預測
- 按價值
市佔率及預測
- 依產品類型（花蕾/大麻花、大麻萃取物）
- 依活性成分（四氫大麻酚（THC）、大麻二酚（CBD）、其他）
- 按配銷通路（B2B、B2C）
- 按應用（慢性疼痛、精神障礙、癌症、癲癇等）
- 按最終用戶產業（製藥和生物技術公司、學術和研究機構、其他）
- 按國家/地區
北美：國家分析
- 美國
- 加拿大
- 墨西哥

第 8 章：歐洲醫用大麻市場展望

市場規模及預測
- 按價值
市佔率及預測
- 依產品類型（花蕾/大麻花、大麻萃取物）
- 依活性成分（四氫大麻酚（THC）、大麻二酚（CBD）、其他）
- 按配銷通路（B2B、B2C）
- 按應用（慢性疼痛、精神障礙、癌症、癲癇等）
- 按最終用戶產業（製藥和生物技術公司、學術和研究機構、其他）
- 按國家/地區
歐洲：國家分析
- 德國
- 馬爾他
- 英國
- 法國
- 丹麥
- 義大利
- 西班牙

第 9 章：亞太地區醫用大麻市場展望

市場規模及預測
- 按價值
市佔率及預測
- 依產品類型（花蕾/大麻花、大麻萃取物）
- 依活性成分（四氫大麻酚（THC）、大麻二酚（CBD）、其他）
- 按配銷通路（B2B、B2C）
- 按應用（慢性疼痛、精神障礙、癌症、癲癇等）
- 按最終用戶產業（製藥和生物技術公司、學術和研究機構、其他）
- 按國家/地區
亞太地區：國家分析
- 澳洲
- 中國
- 泰國
- 韓國
- 印度

第 10 章：南美洲醫用大麻市場展望

市場規模及預測
- 按價值
市佔率及預測
- 依產品類型（花蕾/大麻花、大麻萃取物）
- 依活性成分（四氫大麻酚（THC）、大麻二酚（CBD）、其他）
- 按配銷通路（B2B、B2C）
- 按應用（慢性疼痛、精神障礙、癌症、癲癇等）
- 按最終用戶產業（製藥和生物技術公司、學術和研究機構、其他）
- 按國家/地區
南美洲：國家分析
- 巴西
- 阿根廷
- 哥倫比亞

第 11 章：中東和非洲醫用大麻市場展望

市場規模及預測
- 按價值
市佔率及預測
- 依產品類型（花蕾/大麻花、大麻萃取物）
- 依活性成分（四氫大麻酚（THC）、大麻二酚（CBD）、其他）
- 按配銷通路（B2B、B2C）
- 按應用（慢性疼痛、精神障礙、癌症、癲癇等）
- 按最終用戶產業（製藥和生物技術公司、學術和研究機構、其他）
- 按國家/地區
MEA：國家分析
- 黎巴嫩醫用大麻
- 南非醫用大麻
- 以色列醫用大麻

第 12 章：市場動態

動力
- 慢性病盛行率高
- 醫用大麻合法化
挑戰
- 成本高且並不總是容易獲得
- 消費者接受度較低

第 13 章：市場趨勢與發展

新產品開發
醫藥行業擴大使用醫用大麻。

第 14 章：全球醫用大麻市場：SWOT 分析

第 15 章：波特的五力分析

產業競爭
新進入者的潛力
供應商的力量
客戶的力量
替代產品的威脅

第16章：競爭格局

商業概覽
產品供應
最近的發展
財務（據報導）
主要人員
SWOT分析

第17章：戰略建議

簡介目錄

Product Code: 15430

Global medical cannabis market is expected to register a CAGR of 14.62% and reach USD 47.58 billion by 2028. This is attributed to the growing government fundings, increase in research and development activities (R&D), and growing acceptance across the world. The medical cannabis market is a rapidly growing industry that is gaining acceptance and legal recognition in many countries around the world.

Medical cannabis refers to the use of the cannabis plant or its extracts to treat a range of medical conditions, including chronic pain, nausea, seizures, and anxiety, among others. The market for medical cannabis includes a wide range of products, including dried cannabis flower, oils, capsules, tinctures, and edibles. These products can be administered in different ways, such as smoking, vaporizing, or ingestion, depending on the patient's needs and preferences. One of the main factors driving the growth of the medical cannabis market is increasing public acceptance of cannabis as a legitimate medical treatment option. As more research is conducted into the medical properties of cannabis and more patients report positive outcomes from using cannabis to manage their conditions, demand for medical cannabis products is growing. In Australia, medical cannabis was legalized in 2016, and the number of medical cannabis prescriptions has increased from 1,000 in 2017 to over 100,000 in 2021, according to the surveys conducted by Therapeutic Goods Administration.

The medical cannabis market is benefiting from advancements in cannabis cultivation and production techniques, which are leading to higher-quality products and greater consistency in dosing and potency. The legalization of medical cannabis has made it easier for patients to access this treatment option, especially in places where it was previously illegal. A study published in JAMA Internal Medicine found that states with medical cannabis laws had a 25% lower opioid overdose mortality rate compared to states without medical cannabis laws.

Hence, the medical cannabis market is expected to continue to grow as more patients and healthcare professionals recognize the potential benefits of cannabis as a medical treatment option and as more countries legalize medical cannabis use. This advancements and legalization of medical cannabis in different countries is likely to boost the medical cannabis market in the forecast period.

Legalization of Medical Cannabis to drive the Medical Cannabis Market Growth

The medical cannabis market has been rapidly growing in recent years due to various factors such as changing public attitudes towards the medical cannabis, patient testimonials, and opioid crisis. The legalization of medical cannabis in many countries and states has led to increased availability and accessibility of cannabis for medical use. This has helped to create a legal framework for the production, distribution, and consumption of medical cannabis products, making it easier for patients to access them. Also, there is growing acceptance and awareness about the potential benefits of medical cannabis in treating a wide range of medical conditions such as chronic pain, anxiety, and epilepsy. This has led to increased demand for medical cannabis products, and more people are willing to try them as a potential alternative to traditional medications. As more research is conducted on the potential health benefits of medical cannabis, more evidence is emerging to support medical cannabis use in the treatment of various medical conditions. This has helped to increase the credibility of medical cannabis as a legitimate treatment option, which in turn has encouraged more patients to consider using it. Therefore, the growing occurrences of chronic diseases across the globe is influencing the growth of the global medical cannabis market in the coming years

Legalization increases the number of patients who can access medical cannabis products. When medical cannabis is illegal, patients may be forced to obtain it from the black market, which can be risky and unsafe. Legalization ensures that patients have access to legal and regulated products, which can help to improve the quality of their healthcare. In addition to improving access and safety, legalization creates economic opportunities in the medical cannabis market. Legalization can create jobs, generate tax revenue, and encourage investment in research and development. This can help to drive innovation in the medical cannabis industry, leading to the development of new and more effective products. Countries that legalize medical cannabis can benefit from the economic and public health potential, and manage the legal and social implications. In 2018, the World Health Organization Expert Committee on Drug Dependence, conducted a review of cannabis and its derivatives, including cannabidiol (CBD) and tetrahydrocannabinol (THC), and recommended that cannabis and certain cannabis-related substances should be rescheduled under international drug control conventions to facilitate research into their potential therapeutic uses. Also, WHO stated that CBD has been shown to be effective in treating some forms of epilepsy and tetrahydrocannabinol (THC) may have therapeutic benefits for certain medical conditions such as chronic pain, nausea, and vomiting.

Growing Acceptance and Awareness About the Potential Benefits Drive the Market

Growing acceptance and awareness about the potential benefits of medical cannabis is leading to an increase in demand for medical cannabis in the market. Cannabis contains compounds called cannabinoids, which have been found to have various therapeutic properties for example, cannabinoids can help alleviate symptoms of chronic pain, nausea and vomiting, anxiety, and sleep disorders. In response, more countries and states are legalizing medical cannabis, which further drives the demand. Additionally, advancements in technology have made it easier to extract and produce cannabis-based products, making them more accessible to patients who need them. Therefore, the growing acceptance and awareness of medical cannabis are driving the demand for medical cannabis in the market.

Also, more countries and states legalize medical cannabis, more patients have access to medical cannabis. This has led to a significant increase in demand as patients seek alternative therapies to traditional medicines. Cannabis-based products are being marketed more effectively, with companies emphasizing their therapeutic properties and safety. This has led to increased consumer awareness and demand. The perception of cannabis has shifted in recent years, with more people accepting cannabis potential medical benefits. This has led to greater demand from patients who may have previously been reluctant to try medical cannabis. Therefore, the growing acceptance of people towards the use of medical cannabis is likely to fuel the medical cannabis market in the forecast period.

Medical cannabis has been found to have several potential benefits in treating various medical conditions such as Medical cannabis has shown to be effective in reducing chronic pain, including neuropathic pain, back pain, and arthritis. Cannabis-based products can be effective in reducing nausea and vomiting caused by chemotherapy, HIV/AIDS medications, and other medical treatments. Cannabinoids found in medical cannabis have been shown to reduce symptoms of anxiety and depression. As Per The Data Quoted By The National Conference Of State Legislatures, As of April 24, 2023, the District of Columbia, three territories, and 38 states permit the use of cannabis products for medical purposes.

Hence, the growing acceptance and awareness of medical cannabis has created a significant increase in demand for medical cannabis in the market, with patients seeking alternative therapies for a range of medical conditions.

Favorable Government initiatives and Policies Drive the Medical Cannabis Market Growth

Favorable government initiatives and policies drives the growth of the medical cannabis market as more and more countries and states legalize medical cannabis, there is a growing demand for products that contain cannabis and its derivatives. Government initiatives that support research and development of medical cannabis, provide funding for medical cannabis businesses, and streamline the regulatory process that contribute to the growth of the medical cannabis market.

In addition, government policies that allow for easier access to medical cannabis for patients and healthcare professionals, such as removing barriers to prescribing and dispensing, can help to drive the growth. This can lead to increased adoption of medical cannabis as a treatment option, which in turn can drive demand for related products and services. However, different countries and states have different policies and regulations regarding medical cannabis. Some may have strict requirements for licensing, testing, and quality control, while others may have more relaxed regulations. Therefore, the growth of the medical cannabis market can vary depending on the specific regulatory environment in a given region. According to the data quoted by Savills plc, the majority of the world's legal medicinal cannabis is produced in the UK. The UK output of cannabis-derived pharmaceuticals surged by nearly 500% between 2015 and 2017, reaching 235 tonnes, making it the largest global producer by a significant margin.

Market Segmentation

Global medical cannabis market is segmented based on product type, active ingredient, distribution channel, application, end user, and region. Based on product type, the medical cannabis market is segmented into buds/marijuana flower and cannabis extracts. Based on active ingredient, the medical cannabis market is segmented into Tetrahydrocannabinol (THC), Cannabidiol (CBD), and others. Based on distribution channel, the medical cannabis market is segmented into B2B and B2C. Based on application, the medical cannabis market is divided into chronic pain, mental disorders, cancer, epilepsy, and others. Based on end user, the medical cannabis market is segmented into pharmaceutical & biotechnology companies, academic & research institutions, and others. Based on region, the medical cannabis market is divided into North America, Europe, Asia Pacific, South America, Middle East & Africa.

Company Profiles

Canopy Growth Corporation., Aphria, Inc., Maricann Group, Inc., Tikun Olam - Cannabit Pharmaceuticals Ltd., MedReleaf. Corp., GW Pharmaceuticals plc., Cannabis Sativa, Inc., Medical Marijuana, Inc., Aurora Marijuana Inc., and Cronos Group Inc are some of the key players of global medical Cannabis market.

Report Scope:

In this report, global Medical Cannabis market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Medical Cannabis Market, By Product Type:

Buds/Marijuana Flower

Cannabis Extracts

Medical Cannabis Market, By Active Ingredient:

Tetrahydrocannabinol (THC)

Cannabidiol (CBD)

Others

Medical Cannabis Market, By Distribution Channel:

B2B

B2C

Medical Cannabis Market, By Application:

Chronic Pain

Mental Disorders

Cancer

Epilepsy

Others

Medical Cannabis Market, By End User:

Pharmaceutical & Biotechnology Companies

Academic & Research Institutions

Others

Medical Cannabis Market, By Region:

North America

United States
Mexico
Canada

Europe

Germany
Malta
United Kingdom
France
Denmark
Italy
Spain

Asia-Pacific

Australia
China
Thailand
South Korea
India

South America

Brazil
Argentina
Colombia

Middle East & Africa

Lebanon
South Africa
Israel

Competitive landscape

Company Profiles: Detailed analysis of the major companies present in the global Medical Cannabis market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validations
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trial Analysis

5.1. Ongoing Clinical Trials
5.2. Completed Clinical Trials
5.3. Terminated Clinical Trials
5.4. Breakdown of Pipeline, By Development Phase
5.5. Breakdown of Pipeline, By Status
5.6. Breakdown of Pipeline, By Study Type
5.7. Breakdown of Pipeline, By Region
5.8. Clinical Trials Heat Map

6. Global Medical Cannabis Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Product Type (Buds/Marijuana Flower, Cannabis Extracts)
- 6.2.2. By Active Ingredient (Tetrahydrocannabinol (THC), Cannabidiol (CBD), Others)
- 6.2.3. By Distribution Channel (B2B, B2C)
- 6.2.4. By Application (Chronic Pain, Mental Disorders, Cancer, Epilepsy, Others)
- 6.2.5. By End User Industry (Pharmaceutical & Biotechnology Companies, Academic & Research Institutions, Others)
- 6.2.6. By Region
- 6.2.7. By Company (2022)
6.3. Product Map
- 6.3.1 By Product Type
- 6.3.2 By Active Ingredient
- 6.3.3 By Distribution Channel
- 6.3.4 By Application
- 6.3.5 By End User
- 6.3.4 By Region

7. North America Medical Cannabis Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Product Type (Buds/Marijuana Flower, Cannabis Extracts)
- 7.2.2. By Active Ingredient (Tetrahydrocannabinol (THC), Cannabidiol (CBD), Others)
- 7.2.3. By Distribution Channel (B2B, B2C)
- 7.2.4. By Application (Chronic Pain, Mental Disorders, Cancer, Epilepsy, Others)
- 7.2.5. By End User Industry (Pharmaceutical & Biotechnology Companies, Academic & Research Institutions, Others)
- 7.2.6. By Country
7.3. North America: Country Analysis
- 7.3.1. United States Medical Cannabis Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Product Type
    - 7.3.1.2.2. By Active Ingredient
    - 7.3.1.2.3. By Distribution Channel
    - 7.3.1.2.4. By Application
    - 7.3.1.2.5. By End User Industry
- 7.3.2. Canada Medical Cannabis Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Product Type
    - 7.3.2.2.2. By Active Ingredient
    - 7.3.2.2.3. By Distribution Channel
    - 7.3.2.2.4. By Application
    - 7.3.2.2.5. By End User Industry
- 7.3.3. Mexico Medical Cannabis Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Product Type
    - 7.3.3.2.2. By Active Ingredient
    - 7.3.3.2.3. By Distribution Channel
    - 7.3.3.2.4. By Application
    - 7.3.3.2.5. By End User Industry

8. Europe Medical Cannabis Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Product Type (Buds/Marijuana Flower, Cannabis Extracts)
- 8.2.2. By Active Ingredient (Tetrahydrocannabinol (THC), Cannabidiol (CBD), Others)
- 8.2.3. By Distribution Channel (B2B, B2C)
- 8.2.4. By Application (Chronic Pain, Mental Disorders, Cancer, Epilepsy, Others)
- 8.2.5. By End User Industry (Pharmaceutical & Biotechnology Companies, Academic & Research Institutions, Others)
- 8.2.6. By Country
8.3. Europe: Country Analysis
- 8.3.1. Germany Medical Cannabis Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Product Type
    - 8.3.1.2.2. By Active Ingredient
    - 8.3.1.2.3. By Distribution Channel
    - 8.3.1.2.4. By Application
    - 8.3.1.2.5. By End User Industry
- 8.3.2. Malta Medical Cannabis Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Product Type
    - 8.3.2.2.2. By Active Ingredient
    - 8.3.2.2.3. By Distribution Channel
    - 8.3.2.2.4. By Application
    - 8.3.2.2.5. By End User Industry
- 8.3.3. United Kingdom Medical Cannabis Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecasty
    - 8.3.3.2.1. By Product Type
    - 8.3.3.2.2. By Active Ingredient
    - 8.3.3.2.3. By Distribution Channel
    - 8.3.3.2.4. B y Application
    - 8.3.3.2.5. By End User Industry
- 8.3.4. France Medical Cannabis Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Product Type
    - 8.3.4.2.2. By Active Ingredient
    - 8.3.4.2.3. By Distribution Channel
    - 8.3.4.2.4. By Application
    - 8.3.4.2.5. By End User Industry
- 8.3.5. Denmark Medical Cannabis Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Product Type
    - 8.3.5.2.2. By Active Ingredient
    - 8.3.5.2.3. By Distribution Channel
    - 8.3.5.2.4. By Application
    - 8.3.5.2.5. By End User Industry
- 8.3.6. Italy Medical Cannabis Market Outlook
  - 8.3.6.1. Market Size & Forecast
    - 8.3.6.1.1. By Value
  - 8.3.6.2. Market Share & Forecast
    - 8.3.6.2.1. By Product Type
    - 8.3.6.2.2. By Active Ingredient
    - 8.3.6.2.3. By Distribution Channel
    - 8.3.6.2.4. By Application
    - 8.3.6.2.5. By End User Industry
- 8.3.7. Spain Medical Cannabis Market Outlook
  - 8.3.7.1. Market Size & Forecast
    - 8.3.7.1.1. By Value
  - 8.3.7.2. Market Share & Forecast
    - 8.3.7.2.1. By Product Type
    - 8.3.7.2.2. By Active Ingredient
    - 8.3.7.2.3. By Distribution Channel
    - 8.3.7.2.4. By Application
    - 8.3.7.2.5. By End User Industry

9. Asia-Pacific Medical Cannabis Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Product Type (Buds/Marijuana Flower, Cannabis Extracts)
- 9.2.2. By Active Ingredient (Tetrahydrocannabinol (THC), Cannabidiol (CBD), Others)
- 9.2.3. By Distribution Channel (B2B, B2C)
- 9.2.4. By Application (Chronic Pain, Mental Disorders, Cancer, Epilepsy, Others)
- 9.2.5. By End User Industry (Pharmaceutical & Biotechnology Companies, Academic & Research Institutions, Others)
- 9.2.6. By Country
9.3. Asia-Pacific: Country Analysis
- 9.3.1. Australia Medical Cannabis Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Product Type
    - 9.3.1.2.2. By Active Ingredient
    - 9.3.1.2.3. By Distribution Channel
    - 9.3.1.2.4. By Application
    - 9.3.1.2.5. By End User Industry
- 9.3.2. China Medical Cannabis Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Product Type
    - 9.3.2.2.2. By Active Ingredient
    - 9.3.2.2.3. By Distribution Channel
    - 9.3.2.2.4. By Application
    - 9.3.2.2.5. By End User Industry
- 9.3.3. Thailand Medical Cannabis Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Product Type
    - 9.3.3.2.2. By Active Ingredient
    - 9.3.3.2.3. By Distribution Channel
    - 9.3.3.2.4. By Application
    - 9.3.3.2.5. By End User Industry
- 9.3.4. South Korea Medical Cannabis Market Outlook
  - 9.3.4.1. Market Size & Forecast
    - 9.3.4.1.1. By Value
  - 9.3.4.2. Market Share & Forecast
    - 9.3.4.2.1. By Product Type
    - 9.3.4.2.2. By Active Ingredient
    - 9.3.4.2.3. By Distribution Channel
    - 9.3.4.2.4. By Application
    - 9.3.4.2.5. By End User Industry
- 9.3.5. India Medical Cannabis Market Outlook
  - 9.3.5.1. Market Size & Forecast
    - 9.3.5.1.1. By Value
  - 9.3.5.2. Market Share & Forecast
    - 9.3.5.2.1. By Product Type
    - 9.3.5.2.2. By Active Ingredient
    - 9.3.5.2.3. By Distribution Channel
    - 9.3.5.2.4. By Application
    - 9.3.5.2.5. By End User Industry

10. South America Medical Cannabis Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Product Type (Buds/Marijuana Flower, Cannabis Extracts)
- 10.2.2. By Active Ingredient (Tetrahydrocannabinol (THC), Cannabidiol (CBD), Others)
- 10.2.3. By Distribution Channel (B2B, B2C)
- 10.2.4. By Application (Chronic Pain, Mental Disorders, Cancer, Epilepsy, Others)
- 10.2.5. By End User Industry (Pharmaceutical & Biotechnology Companies, Academic & Research Institutions, Others)
- 10.2.6. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Medical Cannabis Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Product Type
    - 10.3.1.2.2. By Active Ingredient
    - 10.3.1.2.3. By Distribution Channel
    - 10.3.1.2.4. By Application
    - 10.3.1.2.5. By End User Industry
- 10.3.2. Argentina Medical Cannabis Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Product Type
    - 10.3.2.2.2. By Active Ingredient
    - 10.3.2.2.3. By Distribution Channel
    - 10.3.2.2.4. By Application
    - 10.3.2.2.5. By End User Industry
- 10.3.3. Colombia Medical Cannabis Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Product Type
    - 10.3.3.2.2. By Active Ingredient
    - 10.3.3.2.3. By Distribution Channel
    - 10.3.3.2.4. By Application
    - 10.3.3.2.5. By End User Industry

11. Middle East and Africa Medical Cannabis Market Outlook

11.1. Market Size & Forecast
- 11.1.1. By Value
11.2. Market Share & Forecast
- 11.2.1. By Product Type (Buds/Marijuana Flower, Cannabis Extracts)
- 11.2.2. By Active Ingredient (Tetrahydrocannabinol (THC), Cannabidiol (CBD), Others)
- 11.2.3. By Distribution Channel (B2B, B2C)
- 11.2.4. By Application (Chronic Pain, Mental Disorders, Cancer, Epilepsy, Others)
- 11.2.5. By End User Industry (Pharmaceutical & Biotechnology Companies, Academic & Research Institutions, Others)
- 11.2.6. By Country
11.3. MEA: Country Analysis
- 11.3.1. Lebanon Medical Cannabis Market Outlook
  - 11.3.1.1. Market Size & Forecast
    - 11.3.1.1.1. By Value
  - 11.3.1.2. Market Share & Forecast
    - 11.3.1.2.1. By Product Type
    - 11.3.1.2.2. By Active Ingredient
    - 11.3.1.2.3. By Distribution Channel
    - 11.3.1.2.4. By Application
    - 11.3.1.2.5. By End User Industry
- 11.3.2. South Africa Medical Cannabis Market Outlook
  - 11.3.2.1. Market Size & Forecast
    - 11.3.2.1.1. By Value
  - 11.3.2.2. Market Share & Forecast
    - 11.3.2.2.1. By Product Type
    - 11.3.2.2.2. By Active Ingredient
    - 11.3.2.2.3. By Distribution Channel
    - 11.3.2.2.4. By Application
    - 11.3.2.2.5. By End User Industry
- 11.3.3. Israel Medical Cannabis Market Outlook
  - 11.3.3.1. Market Size & Forecast
    - 11.3.3.1.1. By Value
  - 11.3.3.2. Market Share & Forecast
    - 11.3.3.2.1. By Product Type
    - 11.3.3.2.2. By Active Ingredient
    - 11.3.3.2.3. By Distribution Channel
    - 11.3.3.2.4. By Application
    - 11.3.3.2.5. By End User Industry

12. Market Dynamics

12.1. Drivers
- 12.1.1 High prevalence of Chronic
- 12.1.2 Legalization of Medical Cannabis
12.2. Challenges
- 12.2.1 High cost and not always readily available
- 12.2.2 Less acceptance by the Consumer